Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock
NASDAQ · IOVA
10.84
Fundamentals
Market cap
$4.98B
Price / Earnings ratio
-16.9x
Price / Sales ratio
15.1x
Price / Book ratio
6.7x
Return on assets
-39.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

The Motley Fool
Why Iovance Biotherapeutics Stock Was on Fire Today
NeutralIOVASeptember 24, 2026
The Motley FoolNeutral
Why Iovance Biotherapeutics Stock Was on Fire Today
IOVA

MarketBeat
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
NeutralIOVASeptember 19, 2026
MarketBeatNeutral
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
IOVA

Zacks Investment Research
4 Biotech Stocks to Watch as Potential Takeover Targets
NeutralIOVASeptember 18, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks to Watch as Potential Takeover Targets
IOVA

Stocktwits
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
NeutralIOVASeptember 17, 2026
StocktwitsNeutral
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
IOVA
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy5
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
316M209M104M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
1B723M362M0
Revenue to Profit
2025$263.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-391.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

The Motley Fool
Why Iovance Biotherapeutics Stock Was on Fire Today
NeutralIOVASeptember 24, 2026
The Motley FoolNeutral
Why Iovance Biotherapeutics Stock Was on Fire Today
IOVA

MarketBeat
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
NeutralIOVASeptember 19, 2026
MarketBeatNeutral
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
IOVA

Zacks Investment Research
4 Biotech Stocks to Watch as Potential Takeover Targets
NeutralIOVASeptember 18, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks to Watch as Potential Takeover Targets
IOVA

Stocktwits
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
NeutralIOVASeptember 17, 2026
StocktwitsNeutral
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
IOVA

Stocktwits
IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’
NeutralIOVASeptember 15, 2026
StocktwitsNeutral
IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’
IOVA

Stocktwits
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
NeutralIOVASeptember 15, 2026
StocktwitsNeutral
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
IOVA

Stocktwits
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Fed Rate Decision As AI Uncertainty Mounts: IOVA, PLAY, ELMT, RBLX Stocks In Focus
NeutralIOVASeptember 15, 2026
StocktwitsNeutral
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Fed Rate Decision As AI Uncertainty Mounts: IOVA, PLAY, ELMT, RBLX Stocks In Focus
IOVA

Zacks Investment Research
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
NeutralIOVAAugust 27, 2026
Zacks Investment ResearchNeutral
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
IOVA

Zacks Investment Research
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
NeutralIOVAAugust 27, 2026
Zacks Investment ResearchNeutral
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
IOVA

Zacks Investment Research
5 Biotech Stocks Worth Adding to Your Portfolio Now
NeutralIOVAAugust 26, 2026
Zacks Investment ResearchNeutral
5 Biotech Stocks Worth Adding to Your Portfolio Now
IOVA
About Iovance Biotherapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees975
CEODr. Frederick G. Vogt Esq., J.D., Ph.D.
IPO DateOct 15, 2010
HeadquartersSan Carlos, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim CEO, President, General Counsel, Corporate Secretary & Director | 1974 |
| Ms. Corleen M. Roche | Chief Financial Officer | 1966 |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer | 1973 |
| Dr. Raj K. Puri M.D., Ph.D. | Chief Regulatory Officer | 1956 |
| Mr. Daniel G. Kirby | Chief Commercial Officer | 1972 |
| Ms. Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | — |
| Ms. Tracy Winton | Executive Vice President of Human Resources | — |
| Mr. Howard B. Johnson M.B.A. | Chief Business Officer | 1960 |
| Mr. Kevin Smyth | Executive Vice President of Quality | — |
| Dr. Brian Gastman M.D. | Executive Vice President of Translational Medicine & Research | — |
Fundamentals
Valuation
Market cap$4.98B
Price-to-sales ratio15.05
Price-to-book value6.65
Price-earnings ratio-16.90
Return on Equity-50.00%
Return on Sales-124.00%
Return on Assets-39.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.70
Income Statement
Average volume13,250,792
EBITDA$-307.80M
1 year high (52w)$10.98
1 year low (52w)$1.76
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
83% Buy
17% Hold
0% Sell
Target price
$11.00
Est return
1.76%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.7 | -7.7 | -24.5 | +8.6 | ||||||||
| 2022 | -12.8 | -7.7 | +7.9 | -11.5 | -58.8 | +73.0 | +1.6 | -3.6 | -12.4 | +0.0 | -31.7 | -0.3 |
| 2023 | +30.3 | -7.8 | -16.3 | -10.2 | +35.9 | -19.4 | +2.3 | -16.0 | -26.0 | -13.8 | +56.8 | +29.9 |
| 2024 | -4.6 | +97.4 | -11.7 | -17.0 | -29.0 | -4.2 | +8.3 | +42.9 | -13.5 | +11.7 | -16.7 | -18.4 |
| 2025 | -24.9 | -24.8 | -17.6 | +10.5 | -47.4 | -2.3 | +47.7 | -16.8 | -0.9 | -10.9 | +26.7 | +22.4 |
| 2026 | +1.2 | +47.9 | -7.4 | -2.6 | +20.6 | +5.1 | +2.5 | +89.1 | +32.9 |



